Analyst Rating ChangeExpert OpinionPrice Target Update

Behind the Scenes of Eli Lilly's Latest Options Trends

Benzinga•December 04, 2025 at 3:02 PM•Full Content

View Original →

📊 Workflow Status

✓ CompletedCompleted in 36m 21s

clean_raw_article

✓ completed

→

clean_markdown_article

✓ completed

→

analyze_article

✓ completed

→

link_article_to_stories

⊘ skipped

→

analyze_sentiment

✓ completed

Workflow #2406 • Benzinga Article Processing

Started: 15:03:30 • Completed: 15:39:52

View Details →

Detected Companies & Sentiment

Eli Lilly and Company

"neutral mention"

Gist

Eli Lilly's options market shows strong whale activity with mixed bullish and bearish positions, while analysts maintain positive ratings and elevated price targets.

LLM Summary

High-value options trades in Eli Lilly reveal significant whale activity, with nearly equal bullish and bearish positioning across calls and puts, targeting a wide price range of $500–$1140. Despite a slight drop in stock price, analyst consensus remains strongly positive, with average price targets around $1165 and multiple firms upgrading or maintaining 'Outperform' or 'Overweight' ratings. The company's strong pipeline in key therapeutic areas supports the market's confidence.

Full Article Content

Whales with a lot of money to spend have taken a noticeably bullish stance on Eli Lilly.

Looking at options history for Eli Lilly (NYSE: LLY) we detected 28 trades.

If we consider the specifics of each trade, it is accurate to state that 39% of the investors opened trades with bullish expectations and 39% with bearish.

From the overall spotted trades, 14 are puts, for a total amount of $2,580,123 and 14, calls, for a total amount of $625,243.

Projected Price Targets

Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $500.0 to $1140.0 for Eli Lilly over the last 3 months.

Insights into Volume & Open Interest

In today's trading context, the average open interest for options of Eli Lilly stands at 514.47, with a total volume reaching 1,096.00. The accompanying chart delineates the progression of both call and put option volume and open interest for high-value trades in Eli Lilly, situated within the strike price corridor from $500.0 to $1140.0, throughout the last 30 days.

Eli Lilly 30-Day Option Volume & Interest Snapshot

!Options Call Chart

Biggest Options Spotted:

SymbolPUT/CALLTrade TypeSentimentExp. DateAskBidPriceStrike PriceTotal Trade PriceOpen InterestVolumeLLYPUTSWEEPBEARISH12/05/25$101.9$96.75$100.89$1125.00$705.4K0100LLYPUTSWEEPBEARISH12/12/25$21.6$19.5$21.65$1030.00$433.0K352201LLYPUTSWEEPBEARISH12/12/25$14.35$13.65$13.65$1010.00$341.6K561406LLYPUTTRADEBEARISH12/05/25$101.9$96.45$100.63$1125.00$251.5K030LLYPUTTRADEBEARISH01/02/26$53.5$51.65$53.5$1060.00$176.5K3333

About Eli Lilly

Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio for cancer; Mounjaro, Zepbound, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology.

Following our analysis of the options activities associated with Eli Lilly, we pivot to a closer look at the company's own performance.

Current Position of Eli Lilly

- With a trading volume of 379,192, the price of LLY is down by -1.04%, reaching $1022.8.

- Current RSI values indicate that the stock is may be approaching overbought.

- Next earnings report is scheduled for 63 days from now.

Expert Opinions on Eli Lilly

In the last month, 5 experts released ratings on this stock with an average target price of $1165.4.

\\* An analyst from Leerink Partners upgraded its action to Outperform with a price target of $1104.

\\* Maintaining their stance, an analyst from Morgan Stanley continues to hold a Overweight rating for Eli Lilly, targeting a price of $1171.

\\* Maintaining their stance, an analyst from UBS continues to hold a Buy rating for Eli Lilly, targeting a price of $1080.

\\* Maintaining their stance, an analyst from Morgan Stanley continues to hold a Overweight rating for Eli Lilly, targeting a price of $1290.

\\* An analyst from Truist Securities has decided to maintain their Buy rating on Eli Lilly, which currently sits at a price target of $1182.

Whales with a lot of money to spend have taken a noticeably bullish stance on **Eli Lilly**.

Looking at options history for Eli Lilly (NYSE: LLY) we detected 28 trades.

If we consider the specifics of each trade, it is accurate to state that 39% of the investors opened trades with bullish expectations and 39% with bearish.

From the overall spotted trades, 14 are puts, for a total amount of $2,580,123 and 14, calls, for a total amount of $625,243.

### Projected Price Targets

Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $500.0 to $1140.0 for Eli Lilly over the last 3 months.

### Insights into Volume & Open Interest

### Eli Lilly 30-Day Option Volume & Interest Snapshot

!Options Call Chart

### Biggest Options Spotted:

**Symbol****PUT/CALL****Trade Type****Sentiment****Exp. Date****Ask****Bid****Price****Strike Price****Total Trade Price****Open Interest****Volume**LLYPUTSWEEPBEARISH12/05/25$101.9$96.75$100.89$1125.00$705.4K0100LLYPUTSWEEPBEARISH12/12/25$21.6$19.5$21.65$1030.00$433.0K352201LLYPUTSWEEPBEARISH12/12/25$14.35$13.65$13.65$1010.00$341.6K561406LLYPUTTRADEBEARISH12/05/25$101.9$96.45$100.63$1125.00$251.5K030LLYPUTTRADEBEARISH01/02/26$53.5$51.65$53.5$1060.00$176.5K3333

### About Eli Lilly

Following our analysis of the options activities associated with Eli Lilly, we pivot to a closer look at the company's own performance.

### Current Position of Eli Lilly

- With a trading volume of 379,192, the price of LLY is down by -1.04%, reaching $1022.8.
- Current RSI values indicate that the stock is may be approaching overbought.
- Next earnings report is scheduled for 63 days from now.

### Expert Opinions on Eli Lilly

In the last month, 5 experts released ratings on this stock with an average target price of $1165.4.

\\* An analyst from Leerink Partners upgraded its action to Outperform with a price target of $1104.
\\* Maintaining their stance, an analyst from Morgan Stanley continues to hold a Overweight rating for Eli Lilly, targeting a price of $1171.
\\* Maintaining their stance, an analyst from UBS continues to hold a Buy rating for Eli Lilly, targeting a price of $1080.
\\* Maintaining their stance, an analyst from Morgan Stanley continues to hold a Overweight rating for Eli Lilly, targeting a price of $1290.
\\* An analyst from Truist Securities has decided to maintain their Buy rating on Eli Lilly, which currently sits at a price target of $1182.

<p>Whales with a lot of money to spend have taken a noticeably bullish stance on <strong>Eli Lilly</strong>.</p>
<p>Looking at options history for Eli Lilly (NYSE:<a class="ticker" href="https://www.benzinga.com/quote/LLY">LLY</a>) we detected 28 trades.</p>
<p>If we consider the specifics of each trade, it is accurate to state that 39% of the investors opened trades with bullish expectations and 39% with bearish.</p>
<p>From the overall spotted trades, 14 are puts, for a total amount of $2,580,123 and 14, calls, for a total amount of $625,243.</p>
<h3>Projected Price Targets</h3>
<p>Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $500.0 to $1140.0 for Eli Lilly over the last 3 months. </p>
<h3>Insights into Volume &amp; Open Interest</h3>
<p>In today's trading context, the average open interest for options of Eli Lilly stands at 514.47, with a total volume reaching 1,096.00. The accompanying chart delineates the progression of both call and put option volume and open interest for high-value trades in Eli Lilly, situated within the strike price corridor from $500.0 to $1140.0, throughout the last 30 days.</p>
<h3>Eli Lilly 30-Day Option Volume &amp; Interest Snapshot</h3>
<p><img src="https://www.benzinga.com/files/images/story/2025/1764860576_0.png" alt="Options Call Chart" /></p>

<h3>Biggest Options Spotted:</h3>
<p><table style="overflow:auto; height: 90px; display: block;">
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th align="right"><strong>Open Interest</strong></th>
<th align="right"><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>LLY</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>12/05/25</td>
<td>$101.9</td>
<td>$96.75</td>
<td>$100.89</td>
<td>$1125.00</td>
<td>$705.4K</td>
<td align="right">0</td>
<td align="right">100</td>
</tr>
<tr>
<td>LLY</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>12/12/25</td>
<td>$21.6</td>
<td>$19.5</td>
<td>$21.65</td>
<td>$1030.00</td>
<td>$433.0K</td>
<td align="right">352</td>
<td align="right">201</td>
</tr>
<tr>
<td>LLY</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>12/12/25</td>
<td>$14.35</td>
<td>$13.65</td>
<td>$13.65</td>
<td>$1010.00</td>
<td>$341.6K</td>
<td align="right">561</td>
<td align="right">406</td>
</tr>
<tr>
<td>LLY</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>12/05/25</td>
<td>$101.9</td>
<td>$96.45</td>
<td>$100.63</td>
<td>$1125.00</td>
<td>$251.5K</td>
<td align="right">0</td>
<td align="right">30</td>
</tr>
<tr>
<td>LLY</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/02/26</td>
<td>$53.5</td>
<td>$51.65</td>
<td>$53.5</td>
<td>$1060.00</td>
<td>$176.5K</td>
<td align="right">33</td>
<td align="right">33</td>
</tr>
</tbody>
</table></p>
<h3>About Eli Lilly</h3>
<p>Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio for cancer; Mounjaro, Zepbound, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology.</p>
<p>Following our analysis of the options activities associated with Eli Lilly, we pivot to a closer look at the company's own performance.</p>
<h3>Current Position of Eli Lilly</h3>
<ul>
<li>With a trading volume of 379,192, the price of LLY is down by -1.04%, reaching $1022.8.</li>
<li>Current RSI values indicate that the stock is may be approaching overbought.</li>
<li>Next earnings report is scheduled for 63 days from now.</li>
</ul>
<h3>Expert Opinions on Eli Lilly</h3>
<p>In the last month, 5 experts released ratings on this stock with an average target price of $1165.4.</p>
<p><strong>Turn $1000 into $1270 in just 20 days?</strong></p>
<p>20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage"><strong>Click here for access</strong></a>.
&#x2A; An analyst from Leerink Partners upgraded its action to Outperform with a price target of $1104. 
&#x2A; Maintaining their stance, an analyst from Morgan Stanley continues to hold a Overweight rating for Eli Lilly, targeting a price of $1171. 
&#x2A; Maintaining their stance, an analyst from UBS continues to hold a Buy rating for Eli Lilly, targeting a price of $1080. 
&#x2A; Maintaining their stance, an analyst from Morgan Stanley continues to hold a Overweight rating for Eli Lilly, targeting a price of $1290. 
&#x2A; An analyst from Truist Securities has decided to maintain their Buy rating on Eli Lilly, which currently sits at a price target of $1182. </p>
<p>Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Eli Lilly options trades with real-time alerts from <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>.</p>

Metadata

Author:

Benzinga Insights

Image URL:

https://cdn.benzinga.com/files/imagecache/1024x768xUP/images/story/2025/11/06/movers_3.jpg

Tickers:

LLY

Updated At:

December 04, 2025 at 11:03 AM

Benzinga Channels:

Options, Markets

Benzinga Tags:

BZI-UOA

Teaser:

Benzinga Stocks:

LLY (NYSE)

Benzinga Article ID:

49209559